US Tariff Impact on Global Pharmaceutical Supply Chains
The United States has introduced steep tariffs, up to 100%, on imported branded medicines as part of an effort to reshape global pharmaceutical supply chains. These tariffs, signed into effect by President Donald Trump, aim to push companies to either accept government-mandated pricing terms or relocate manufacturing to the US.
Key Features of the Tariff Policy
- The tariffs will not affect generic medicines, which are outside the scope of this policy.
- Exemptions apply to companies complying with pricing terms or shifting production to the US, potentially lowering tariffs to 10-20%.
- The tariffs are scheduled to start between August and September 2026, after a transition period of 120–180 days.
Global and Regional Impact
- Major exporters of high-value drugs to the US such as Ireland, Germany, and Switzerland will be affected.
- Countries with trade arrangements with the US, like the EU and Japan, are not exempt unless companies within those countries comply individually.
- European pharmaceutical firms might negotiate tariff reductions through limited price cuts or US investments.
Impact on India
- India's generic medicines, which form 90% of US drug use, are currently exempt from tariffs to prevent shortages.
- Indian firms producing branded or speciality drugs, or supplying inputs for patented medicines, might face future tariff pressures.
- India exported $9.7 billion worth of pharmaceuticals to the US in the previous year, making up 38% of its global pharma exports.
Case Study: Sun Pharmaceutical Industries
- Sun Pharma is more vulnerable due to its speciality portfolio in the US, which includes patented drugs.
- Despite potential vulnerabilities, Sun Pharma's diversified manufacturing base reduces direct tariff impact.
- Key products like Tildrakizumab (Ilumya) are manufactured in Germany/South Korea, reducing exposure to tariffs.
Conclusion
While the immediate impact on India is limited, the exemption for generics is temporary. Future policy changes could introduce strategic uncertainties and affect India's position in the global pharmaceutical supply chain.
